TWTimothy A. Watkins

Timothy A. Watkins

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Timothy A. Watkins has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Reply to McMahon et al

    by Timothy A Watkins, Jacqueline K Brockhurst, Gregory Germain, Ellen F Foxman

  • Open Access

    Nasal biomarker testing to rule out viral respiratory infection and triage samples: a test performance study

    by Julien A.R. Amat, Sarah N. Dudgeon, Nagarjuna R. Cheemarla, Timothy A. Watkins, Alex B. Green, H. Patrick Young, David R. Peaper, Marie L. Landry, Wade L. Schulz, Ellen F. Foxman


  • Detection of Live Attenuated Measles Virus in the Respiratory Tract Following Subcutaneous Measles-Mumps-Rubella Vaccination

    by Timothy A Watkins, Jacqueline K Brockhurst, Gregory Germain, Diane E Griffin, Ellen F Foxman

    The live attenuated measles vaccine is extremely effective in preventing measles and induces mucosal immunity in the respiratory tract, however the mechanism is not known. We show that live attenuated measles virus (LAMV) RNA is frequently detected in the respiratory tract 7-21 days after subcutaneous measles-mumps-rubella (MMR) vaccination in healthy children (n = 5/20) and macaques (n = 6/8). Replicating LAMV was isolated from the lungs of 2 macaques, with no evidence of transmission to unvaccinated individuals. These observations suggest that LAMV in the respiratory tract may play a role in the development of robust mucosal immunity following MMR vaccination.


  • Open Access

    Considerations for viral co-infection studies in human populations

    by Taylor Chin, Ellen F. Foxman, Timothy A. Watkins, Marc Lipsitch

    When respiratory viruses co-circulate in a population, individuals may be infected with multiple pathogens and experience possible virus–virus interactions, where concurrent or recent prior infection with one virus affects the infection process of another virus. While experimental studies have provided convincing evidence for within-host mechanisms of virus–virus interactions, evaluating evidence for viral interference or potentiation using population-level data has proven more difficult. Recent studies have quantified the prevalence of co-detections using populations drawn from clinical settings. Here, we focus on selection bias issues associated with this study design. We provide a quantitative account of the conditions under which selection bias arises in these studies, review previous attempts to address this bias, and propose unbiased study designs with sample size estimates needed to ascertain viral interference. We show that selection bias is expected in cross-sectional co-detection prevalence studies conducted in clinical settings, except under a strict set of assumptions regarding the relative probabilities of being included in a study limited to individuals with clinical disease under different viral states. Population-wide studies that collect samples from participants irrespective of their clinical status would meanwhile require large sample sizes to be sufficiently powered to detect viral interference, suggesting that a study’s timing, inclusion criteria, and the expected magnitude of interference are instrumental in determining feasibility.


  • Open Access

    High burden of viruses and bacterial pathobionts drives heightened nasal innate immunity in children

    by Timothy A. Watkins, Alex B. Green, Julien A.R. Amat, Nagarjuna R. Cheemarla, Katrin Hänsel, Richard Lozano, Sarah N. Dudgeon, Gregory Germain, Marie L. Landry, Wade L. Schulz, et al.

    Studies during the COVID-19 pandemic showed that children had heightened nasal innate immune responses compared with adults. To evaluate the role of nasal viruses and bacteria in driving these responses, we performed cytokine profiling and comprehensive, symptom-agnostic testing for respiratory viruses and bacterial pathobionts in nasopharyngeal samples from children tested for SARS-CoV-2 in 2021–22 (n = 467). Respiratory viruses and/or pathobionts were highly prevalent (82% of symptomatic and 30% asymptomatic children; 90 and 49% for children <5 years). Virus detection and load correlated with the nasal interferon response biomarker CXCL10, and the previously reported discrepancy between SARS-CoV-2 viral load and nasal interferon response was explained by viral coinfections. Bacterial pathobionts correlated with a distinct proinflammatory response with elevated IL-1β and TNF but not CXCL10. Furthermore, paired samples from healthy 1-year-olds collected 1–2 wk apart revealed frequent respiratory virus acquisition or clearance, with mucosal immunophenotype changing in parallel. These findings reveal that frequent, dynamic host–pathogen interactions drive nasal innate immune activation in children.


  • Open Access

    Dynamic innate immune response determines susceptibility to SARS-CoV-2 infection and early replication kinetics

    by Nagarjuna R. Cheemarla, Timothy A. Watkins, Valia T. Mihaylova, Bao Wang, Dejian Zhao, Guilin Wang, Marie L. Landry, Ellen F. Foxman

    Initial replication of SARS-CoV-2 in the upper respiratory tract is required to establish infection, and the replication level correlates with the likelihood of viral transmission. Here, we examined the role of host innate immune defenses in restricting early SARS-CoV-2 infection using transcriptomics and biomarker-based tracking in serial patient nasopharyngeal samples and experiments with airway epithelial organoids. SARS-CoV-2 initially replicated exponentially, with a doubling time of ∼6 h, and induced interferon-stimulated genes (ISGs) in the upper respiratory tract, which rose with viral replication and peaked just as viral load began to decline. Rhinovirus infection before SARS-CoV-2 exposure accelerated ISG responses and prevented SARS-CoV-2 replication. Conversely, blocking ISG induction during SARS-CoV-2 infection enhanced viral replication from a low infectious dose. These results show that the activity of ISG-mediated defenses at the time of SARS-CoV-2 exposure impacts infection progression and that the heterologous antiviral response induced by a different virus can protect against SARS-CoV-2.